Related Experiment Video
Updated: May 5, 2026
08:49
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
Published on: March 18, 2020
11.1K
High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects.
Lei Liu1,2, Saisai Chen3, Meng Ding4
1Department of General Surgery, Fuyang Hospital of Traditional Chinese Medicine, Fuyang, China.
Frontiers in Oncology
|May 4, 2026
Summary
High-throughput screening advances cancer immunotherapy by identifying targets and substances to overcome resistance in adoptive T cell therapy (ACT). This accelerates the development of more effective ACT strategies for clinical application.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Adoptive T cell therapy (ACT) shows promise in cancer immunotherapy.
- Clinical efficacy of ACT is frequently hindered by primary resistance.
- Overcoming resistance is crucial for enhancing ACT effectiveness.
Purpose of the Study:
- To review advancements in high-throughput screening (HTS) for optimizing ACT.
- To highlight HTS applications in genetic and non-genetic screening relevant to ACT.
- To provide guidance for future ACT research and clinical translation.
Main Methods:
- Review of recent literature on high-throughput screening technologies.
- Analysis of HTS applications in genetic screening of T cells and tumor cells.
- Examination of non-genetic screening methods for small molecules and delivery systems.
Main Results:
- HTS technologies are essential for identifying significant targets and substances.
- HTS accelerates the development of advanced ACT strategies.
- Applications span genetic screening and discovery of therapeutic agents.
Conclusions:
- High-throughput screening is pivotal for overcoming resistance in ACT.
- Continued advancements in HTS will drive innovation in cancer immunotherapy.
- HTS offers valuable insights for future ACT research and clinical practice.
